Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
企業コードRGEN
会社名Repligen Corp
上場日Apr 29, 1986
設立日1981
最高経営責任者「CEO」Mr. Olivier Loeillot
従業員数1778
証券種類Ordinary Share
決算期末Apr 29
本社所在地Building 1, Suite 100
都市WALTHAM
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号02453
電話番号17814499560
ウェブサイトhttps://www.repligen.com/
企業コードRGEN
上場日Apr 29, 1986
設立日1981
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし